Cureledger

End Rare Disease

[Cureledger @CureLedger]

🚀 CureLedger: Building the future of verifiable health data marketplaces. 🌐💊

We're opening @teamrymedi's tested, scalable infrastructure to unlock trust, transparency, and innovation in healthcare and research!

#DeSci #Blockchain #HealthData #Innovation

[Cureledger @CureLedger]

Half a million Americans live with conditions newborn screening identified. Decades of data already exist. The platform makes it licensable.

[Cureledger @CureLedger]

Half a million Americans live with conditions newborn screening identified. Decades of data already exist. The platform makes it licensable.

[Cureledger @CureLedger]

If you ran a pharma R&D budget today and saw the new math, which rare disease would you fund first?

[Cureledger @CureLedger]

Pharma left rare disease behind because the math did not pencil. Here is what just changed.

[Cureledger @CureLedger]

For decades, rare disease was the charity vertical of pharma. The math has changed. AI plus cohort proofs plus contributor-owned platforms equals a real market. It is no longer good business to leave rare diseases behind. 1/12
https://t.co/7jqHOW9Zpf

[Cureledger @CureLedger]

Twenty years of EDS forum threads, symptom logs, brace ratings. The data was generated. The pattern of capture is the issue. Ownership is the fix.

[Cureledger @CureLedger]

If your daily rare-disease data is about to become AI training input, which protection do you want first: ownership, withdrawal, benefit-sharing, or privacy that survives bankruptcy?

[Cureledger @CureLedger]

AI drug discovery turned our daily data into the most valuable raw material in medicine. Without ownership infrastructure that is extraction.

[Cureledger @CureLedger]

Ethical AI that puts human dignity first became a hot topic with Pope Leo XV's publication of Magnifica Humanitas. Cureledger is committed to improving human life mission. Read our comment to the FDA on AI-enhanced Clinical Trials on making this real for rare diseases.

[Cureledger @CureLedger]

AI drug discovery just made our data the most valuable raw material in medicine. 23andMe showed what happens without ownership: 15 million genomes on a bankruptcy auction block. We built the platform that flips it. 1/12 ⬇️
https://t.co/njuHAX3nc7

[Cureledger @CureLedger]

Cohort size alone is a poor index of evidential quality. A longer read on the scaling logic. https://t.co/V1hAAdYVEV

[Cureledger @CureLedger]

Newborn-screening families hold decades of biomarker data sitting unused in state lab archives. AI was waiting for this.

[Cureledger @CureLedger]

RWE and clinic teams are often held back by data that never exists at the resolution of lived disease. https://t.co/iJdU5H7WcH

[Cureledger @CureLedger]

If AI cures a rare disease in the next three years, which one would you want it to be?

[Cureledger @CureLedger]

The near-term constraint is not more compute, but data that can survive consent review and later reuse. https://t.co/Wd9zLMVc88

[Cureledger @CureLedger]

AI is going to cure rare diseases. Using our data. We built the platform that pays us when it does.

[Cureledger @CureLedger]

Four things converged. Cures are reachable. Here's the platform that gets us paid.
https://t.co/VISnoXMqjx

[Cureledger @CureLedger]

AI is going to cure rare diseases. Using our data. Four things converged and made it possible. So we built the platform that pays us when our data builds the cure. 1/12 ⬇️
https://t.co/VISnoXMqjx

[Cureledger @CureLedger]

Five sections: inflection, the legacy data layer in rare, architecture, market, moat. https://t.co/gwx9sMAYKL

[Cureledger @CureLedger]

A short history: from a metabolic result to a national program, and the public-health politics in between. https://t.co/nmwVvFWqGJ